Alamar Biosciences, in collaboration with the Alzheimer's Disease Data Initiative and Gates Ventures, launches a major global project profiling over 40,000 plasma samples using ultra-sensitive NULISA™ technology to identify biomarkers for Alzheimer’s and related dementias. This initiative integrates cutting-edge proteomics, clinical outcomes, and data sharing to accelerate biomarker discovery and therapy development, heralding a new era in precision neurodegenerative disease research.